Biotech

All Articles

Amgen records initial stage 3 win for $400M eczema drug

.Amgen has actually shared (PDF) the initial period 3 data on its $400 million eczema drug, linking ...

Biogen, UCB file period 3 lupus win after neglecting earlier test

.Biogen and also UCB's bank on developing right into phase 3 astride an unsuccessful study looks to ...

Aptadir hopes new RNA preventions can easily reverse tricky cancers

.Italian biotech Aptadir Therapeutics has introduced with the assurance that its pipeline of preclin...

Wave surfs DMD excellence to regulatory authorities' doors, sending out stock up

.Surge Lifestyle Sciences has fulfilled its target in a Duchenne muscle dystrophy (DMD) research, in...

Sanofi plucks new CSO coming from in-stealth biotech

.After a couple of years in biotech, Mike Quigley, Ph.D., is actually coming back to the pharma fold...

Achilles splashes cell treatment plan, prepares for layoffs after missing 'office practicality' goals

.Achilles Rehabs has actually shreded its own approach. The English biotech is actually quiting work...

Aligos heralds phase 2 MASH succeed, lowering liver excess fat up to 46%

.Aligos Therapeutics is actually trumpeting a midstage win in metabolic-dysfunction associated steat...

Basilea scores $268M BARDA backing for antifungals, anti-biotics

.Basilea Pharmaceutica's work developing new antifungals has acquired a significant improvement comi...

Capricor markets Europe civil rights to late-stage DMD treatment for $35M

.Possessing currently gathered up the USA legal rights to Capricor Rehabs' late-stage Duchenne muscl...

FDA junks adcomm for Applied's uncommon disease drug

.After dismissing the decision date for Applied Therapies' metabolic condition medicine govorestat, ...